Sorted By:



PhRMA  |  From PhRMA

click here for even more information on 340B.

340B Then & Now

PhRMA  |  Graphic

A closer look at how the 340B program has evolved since its creation in 1992.

340B Drug Discount Program Pocket Card

PhRMA  |  Fact Sheet

Clinics eligible for the 340B program as part of a federal grant program are required to reinvest any additional resources into services for the vulnerable communities they serve, while current rules allow hospitals participating in the program to profit by reselling discounted medicines with no requirement to ensure patients benefit from the discounts.

340B 101

PhRMA  |  Report

Download the deck to learn more about the 340B program.

PhRMA Statement on 340B PAUSE Act

PhRMA  |  Press Release

“This legislation provides Congress with a much-needed opportunity to closely evaluate 340B and ways it can be fixed to the benefit of patients.”

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

PhRMA  |  Blog Post

To learn more about the 340B program, visit

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

PhRMA  |  Blog Post

This markup becomes even more egregious, 79 percent, if the hospital was able to acquire the drug at the 340B discounted price.

340B Spotlight: Myth vs. Fact

PhRMA  |  Graphic

Congress created the 340B program in 1992 to help health care safety-net facilities that serve a large proportion of needy or uninsured patients have access to discounted prescription medicines.

340B Spotlight: Audit findings show importance of increased oversight of 340B program

PhRMA  |  Blog Post

Learn more about the 340B program at

340B Spotlight: New analysis finds 340B program growth continues to accelerate despite false claims

PhRMA  |  Blog Post

Read the full BRG report here and learn more about 340B here.

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

PhRMA  |  Blog Post

Learn more at

Legislative and Regulatory History of the Evolution of 340B Program

PhRMA  |  Fact Sheet

The 340B program was created by Congress in 1992 to help vulnerable or uninsured patients access prescription medicines at safety net facilities.

340B Program in urgent need of expanded Congressional and administrative oversight, reform

PhRMA  |  Press Release

As additional evidence that the program has expanded beyond true safety net hospitals, the analysis revealed that about one-fifth of 340B hospitals provide 80 percent of all charity care delivered by 340B hospitals.

340B Drug Purchases and Population without Drug Coverage

PhRMA  |  Graphic

Drug purchases through the 340B program will continue to rise, at the same time the share of the population without prescription drug coverage will nearly drop in half.

New Analysis: 340B Program Shifting Delivery of Physician-Administered Medicines to More Expensive Hospital Settings

PhRMA  |  Press Release

To learn more about the 340B program and ways it could be fixed, visit

PhRMA Special 301 Submission 2017

PhRMA  |  Policy Paper

The Special 301 statute calls upon the Office of the United States Trade Representative (USTR) to address in its review foreign country practices that deny fair and equitable market access to U.S. persons that rely upon intellectual property (IP) protection.

340B Percent of Pharmaceutical Sales

PhRMA  |  Graphic


How 340B Discounts Work

Chartpack  |  From Our Network

Manufacturers provide 340B hospitals with discounted medicines, who then provide the medicines to patients, and then insurers reimburse the hospitals at a full negotiated rate and the hospital keeps the difference as profit.

340B: Past and Present

Chartpack  |  From Our Network

When it was created in 1992, 340B was envisioned as a small program however insufficient guidance, historically weak oversight, and other factors have led to dramatic program growth, driven by the participation of large hospitals in the 340B program.

PhRMA Statement on AARP Prescription Drug Report

PhRMA  |  Press Release

Washington, D.C. (November 16, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today:  “In AARP’s skewed view of the world, medicines are always looked at as a cost and never seen as a sa...

340B Spotlight: A Look at 340B Purchases

PhRMA  |  Blog Post

By 2019, the Berkeley Research Group projects the 340B program will account for 8.0 percent of sales.

340B Spotlight: A look at 340B eligibility and charity care

PhRMA  |  Blog Post

Stricter 340B eligibility criteria are needed to address the market distorting effects of the 340B program.

340B Mega Guidance

PhRMA  |  Blog Post

Subscribe to industry alerts for issues such as 340B, access to medicines & more.

340B Spotlight: A lack of charity care among 340B hospitals

PhRMA  |  Blog Post

  For more check out our chart pack or stay up-to-date on the latest 340B news with our 340B Spotlight posts.

How 340B discounts work

PhRMA  |  Blog Post

Learn more about 340B at and stay tuned to 340B Spotlight posts for more on this important program and the changes needed to ensure it benefits those it was intended to help.

You have reviewed the first 25 results out of 426. Each page contains 25 results. You're on page 1.

prev 1 2 3 4 5 6 next